Telix Pharmaceuticals Limited Unsponsored ADR (TLX) AI Stock Analysis

14 Followers

Telix Pharmaceuticals Limited Unsponsored ADR

(NASDAQ:TLX)

Select Model

Rating:57Neutral

Price Target:$10.50▲(7.97% Upside)

Action:reiterated

Date:10/22/26

The score is held back primarily by weakening recent financial quality (negative 2025 operating/free cash flow and higher leverage) and a demanding valuation (P/E ~98). Offsetting these, the latest earnings call was notably strong with robust growth, improving profitability metrics, and reaffirmed guidance near the upper end, while technicals remain weak with bearish momentum signals.

Positive Factors

Strong revenue growthSustained growth across the core Precision Medicine business indicates strong product demand and expanding commercial execution. The combination of higher group revenue and faster segment growth supports continued scale benefits, investment capacity, and a stronger competitive position over the next several quarters.

Negative Factors

Negative recent cash generationThe reversal from positive operating and free cash flow in 2023–2024 to materially negative figures in 2025 weakens earnings quality and increases funding reliance. Persistent cash demands could constrain investment flexibility unless commercial growth converts more consistently into cash.

Telix Pharmaceuticals Limited Unsponsored ADR (TLX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $3.23B
Dividend Yield: ―
Average Volume (3M): 346.59K
Price to Earnings (P/E): 97.0
Beta (1Y): 1.49
Revenue Growth: 33.78%
EPS Growth: 198.49%
Country: US
Employees: 1,152
Sector: General
Sector Strength: 55
Industry: Biotechnology

Telix Pharmaceuticals Limited Unsponsored ADR Business Overview & Revenue Model

Company Description

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therape...

How the Company Makes Money

Telix generates revenue primarily by selling radiopharmaceutical products and related services. Its revenue model includes: (1) Commercial product sales: Revenue from the manufacture and sale of approved radiopharmaceuticals supplied to healthcare pr...

Telix Pharmaceuticals Limited Unsponsored ADR Earnings Call Summary

Earnings Call Date:Aug 19, 2026(Q2-2026)|% Change Since:-19.76%|Next Earnings Date:Aug 21, 2020

Earnings Call SentimentPositive

The call was strongly positive, supported by 22% group revenue growth, 146% EBITDA growth, 27% Precision Medicine growth, consecutive PSMA market-share gains, successful Gozellix adoption, a strengthened cash position and broad clinical and regulatory progress. The main negatives were Zircaix's corrected complete response letter and related manufacturing deficiencies, the uncertain Pixlumi review timeline, and the fact that the existing PSMA market is already approximately two-thirds penetrated. Overall, the highlights significantly outweigh the lowlights.

Positive Updates

Strong First-Half Financial Performance

H1 2026 revenue reached $477 million, up 22% compared with H1 2025. EBITDA improved 146% year-on-year to $52 million, while net profit after tax increased to $38 million. Management attributed the performance to robust commercial execution, strong demand for precision medicine products and continued control of operating expenditure.

Negative Updates

Zircaix Corrected Complete Response Letter

Telix received a corrected complete response letter from the FDA for Zircaix. The company said the resubmission must fully address outstanding items, particularly third-party manufacturing deficiencies, before filing.

Company Guidance

For 2026, Telix maintained full year revenue guidance of between $950 million and $970 million, expects that to land at the upper end of the range, and expects continued growth in excess of 20% year-on-year of its Precision Medicine business; full-time guidance does not reflect unapproved products, providing the potential for upside. R&D guidance was updated to a range of $230 million to $270 million. Management said Zircaix resubmission in the next month or two would be a reasonable assumption, while Pixlumi’s standardized review process is around an 18-month process and can go a little bit faster, a little bit slower depending on clock stops and review times.

Telix Pharmaceuticals Limited Unsponsored ADR Financial Statement Overview

Summary

Strong multi-year revenue ramp and solid gross profitability, but 2025 showed weaker quality with a return to a small net loss, higher leverage (debt exceeding equity), and a sharp deterioration to negative operating and free cash flow.

Income Statement

68Positive

Balance Sheet

55Neutral

Cash Flow

40Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	886.07M	789.77M	783.21M	502.55M	160.10M	7.60M
Gross Profit	461.94M	419.47M	509.68M	314.39M	94.93M	5.05M
EBITDA	31.02M	52.30M	100.57M	22.97M	-92.84M	-70.07M
Net Income	33.43M	―	49.92M	5.21M	-104.08M	-80.51M
Balance Sheet
Total Assets	1.36B	1.18B	1.52B	398.30M	255.35M	109.81M
Cash, Cash Equivalents and Short-Term Investments	251.82M	141.82M	710.35M	123.24M	116.33M	22.04M
Total Debt	579.64M	466.96M	581.45M	17.45M	10.45M	2.54M
Total Liabilities	873.85M	766.49M	948.22M	249.39M	175.35M	106.17M
Stockholders Equity	487.49M	415.24M	568.21M	148.91M	80.01M	2.16M
Cash Flow
Free Cash Flow	-57.14M	-54.25M	28.71M	14.21M	-71.01M	-60.67M
Operating Cash Flow	-11.76M	-16.99M	43.03M	23.88M	-63.97M	-59.33M
Investing Cash Flow	-60.83M	-280.93M	-135.17M	-25.49M	-17.00M	-2.73M
Financing Cash Flow	117.31M	-3.65M	638.92M	10.19M	174.96M	2.85M

Telix Pharmaceuticals Limited Unsponsored ADR Technical Analysis

Technical Analysis SentimentNeutral

Last Price9.72

Price Trends

50DMA10.76Negative

100DMA10.94Negative

200DMA9.98Negative

Market Momentum

MACD-0.34Negative

RSI46.96Neutral

STOCH72.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLX, the sentiment is Neutral. The current price of 9.72 is above the 20-day moving average (MA) of 9.68, below the 50-day MA of 10.76, and below the 200-day MA of 9.98, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 72.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TLX.

Telix Pharmaceuticals Limited Unsponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TLX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TLX	57Neutral	$3.22B	97.04	7.24%	―	33.78%	198.49%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DRTS	53Neutral	$1.27B	-13.48	-138.12%	―	―	-115.15%
IMCR	52Neutral	$1.67B	-50.01	-7.96%	―	13.01%	―
IMTX	44Neutral	$960.66M	-3.61	-52.19%	―	-44.50%	-80.18%
URGN	43Neutral	$1.24B	-19.77	53.97%	―	159.29%	61.62%
NBTX	41Neutral	$1.64B	-26.44	89.71%	―	―	―

* General Sector Average

Performance Comparison

TLX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TLX	Telix Pharmaceuticals Limited Unsponsored ADR	9.72	0.21	2.26%
URGN	Urogen Pharma	26.10	2.18	9.11%
IMTX	Immatics N.V.	6.69	-3.29	-32.97%
IMCR	Immunocore Holdings Plc	31.65	-3.72	-10.52%
NBTX	Nanobiotix Sa ADR	32.95	12.68	62.56%
DRTS	Alpha Tau	14.02	10.15	262.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2026

Telix Pharmaceuticals Limited Unsponsored ADR AI Stock Analysis